Research programme: Gaucher's disease therapy - BioDelivery SciencesAlternative Names: Biorazyme; Gaucher's disease therapy research programme - BioDelivery Science
Latest Information Update: 11 Apr 2007
At a glance
- Originator BioDelivery Sciences International
- Mechanism of Action Enzyme replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Gaucher's disease
Most Recent Events
- 09 Dec 2004 Preclinical trials in Gaucher's disease in USA (PO)